Replies to post #6428 on Galena Biopharma fka GALE

[Euripides90]

Here's more bullish coverage for Galena: finally made Zacks' #2 Buy list too bad it had to get so low in PPS to get there, despite the strong Q4 report and positive signs for short and long-term growth.

(Nice that warrants on the PO have to be exercised @$2.08, really that should've been the base price based on the reports and target.)


How Galena (GALE) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - ZACKS - Wed Mar 18, 7:38AM CDT



One stock that might be an intriguing choice for investors right now is Galena Biopharma, Inc. (GALE). This is because this security in the biomedical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the biomedical space as it currently has a Zacks Industry Rank of 74 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Galena is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the past month, current quarter estimates have narrowed from a loss of 11 cents a share to a loss of 9 cents a share, while current year estimates have narrowed from a loss of 34 cents a share to a loss of 33 cents a share. This has helped GALE to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.

So, if you are looking for a decent pick in a strong industry, consider Galena. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.